Acute Myelocytic Leukemia Clinical Trial
Official title:
A Phase II Study of Ribavirin in Refractory of Relapsed Acute Myelocytic Leukemia M4 and M5 Subtypes
The purpose of this study is to determine if ribavirin (a drug commonly used to treat hepatitis C) also has activity in the treatment of patients with refractory or relapsed acute myeloid leukemia (AML) of the M4 and M5 subtype.
The eukaryotic translation initiation factor eIF4E is dysregulated in many human malignancies, including a subset of myeloid leukemia (M4/M5 AML and blast crisis CML). eIF4E overexpression leads to oncogenic transformation. Ribavirin impedes eIF4E mediated transformation in vitro, in primary human specimens and in animal models. While ribavirin has been used extensively for the treatment of viral hepatitis C and its safety profile has been well defined, it has never been used in patients with AML. This study will establish the efficacy and safety of ribavirin in M4/M5 AML patients. In addition, this study will also include correlative studies to determine the effect of ribavirin on eIF4E activity and eIF4E related pathways in M4/M5 AML patients. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT02244658 -
Recombinant Human Thrombopoietin (rhTPO) in Management of Chemotherapy-induced Thrombocytopenia in Acute Myelocytic Leukemia
|
Phase 3 | |
| Completed |
NCT01462578 -
Treatment of Patients With Myelodysplastic Syndrome or Acute Myelocytic Leukemia With an Impending Hematological Relapse With Azacitidine (Vidaza)
|
Phase 2 | |
| Completed |
NCT01188798 -
Methotrexate or Pentostatin for Graft-versus-host Disease Prophylaxis in Risk-adapted Allogeneic Bone Marrow Transplantation for Hematologic Malignancies
|
Phase 3 | |
| Recruiting |
NCT06105658 -
Safety and Efficacy of Unrelated Umbilical Cord Blood Microtransplantation in Patients With AML
|
Phase 2 | |
| Completed |
NCT00854646 -
Phase I Study of ON 01910.Na in Refractory Leukemia or Myelodysplastic Syndrome (MDS)
|
Phase 1 | |
| Completed |
NCT00152139 -
Stem Cell Transplantation for Patients With Hematologic Malignancies
|
Phase 3 | |
| Completed |
NCT00061581 -
Experimental Bone Marrow Transplant Protocol
|
Phase 2 | |
| Completed |
NCT01167166 -
Safety and Efficacy of 72-hour and 120-hour Infusion of Rigosertib in Acute Myeloid Leukemia (AML) and Acute Lymphoid Leukemia (ALL)
|
Phase 1/Phase 2 | |
| Completed |
NCT01474681 -
Safety and Tolerability of HSC835 in Patients With Hematological Malignancies
|
Phase 1/Phase 2 | |
| Terminated |
NCT02255162 -
Lenalidomide in Combination With Microtransplantation as Post-remission Therapy in AML
|
Phase 1 | |
| Active, not recruiting |
NCT01809392 -
Decitabine Augments for Post Allogeneic Stem Cell Transplantation in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndrome
|
Phase 2/Phase 3 | |
| Recruiting |
NCT00155844 -
Studies on the Significance of CXCR4-CXCL12 on Leukemic Cells Passing Through"Marrow-Blood Barrier"
|
N/A | |
| Recruiting |
NCT03796390 -
Study Evaluating Safety and Efficacy of CAR-T Cells Targeting CD123 in Patients With Acute Myelocytic Leukemia
|
Phase 1 | |
| Terminated |
NCT01621477 -
T-Cell Replete Haploidentical Donor Hematopoietic Stem Cell Plus Natural Killer (NK) Cell Transplantation in Patients With Hematologic Malignancies Relapsed or Refractory Despite Previous Allogeneic Transplant
|
Phase 2 | |
| Completed |
NCT00015587 -
Molecular Epidemiology of Childhood Leukemia (Aka The California Childhood Leukemia Study)
|
N/A |